Physician profile

Lewis Johnson

Urology · Muncie, IN

NPI 1295979474

$709.39

in general payments reported to CMS, 2019-2025

11 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$272.05

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astellas Pharma US INC $245.86 2019-2022
Conmed Corporation $163.14 2024 Airseal
Boston Scientific Corporation $122.79 2022-2024 Rezum Generator
Myovant Sciences INC. $73.11 2021-2022
Olympus America INC. $18.63 2019
Convatec INC. $16.11 2021
Tolmar Pharmaceuticals, INC. $15.01 2019
Pfizer INC. $14.32 2019
Astrazeneca Pharmaceuticals LP $14.23 2021
Abbvie INC. $13.68 2022
Janssen Biotech, INC. $12.51 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Lewis Johnson

$709.39

in general payments reported 2019-2025

Years
2019-2024
Top company
Astellas Pharma US INC

https://glasscript.com/doctor/485340/lewis-johnson

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.